Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method

被引:39
作者
Mwenifumbo, JC
Myers, MG
Wall, TL
Lin, SK
Sellers, EM
Tyndale, RF
机构
[1] Univ Toronto, Toronto, ON M5S 1A8, Canada
[2] Vet Med Res Fdn, San Diego, CA USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Taipei City Psychiat Ctr, Dept Addict Sci, Taipei, Taiwan
[5] Ctr Addict Mental Hlth, Toronto, ON, Canada
[6] Dept Pharmacol, Toronto, ON, Canada
关键词
CYP2A6; genotype; haplotype; nicotine metabolism; pharmacogenetics; polymorphism;
D O I
10.1097/01213011-200503000-00008
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cytochrome P450 2A6 is the main human nicotine metabolizing enzyme coded for by a highly polymorphic gene, CYP2A6. CYP2A6*7, CYP2A6*8 and CYP2A6*10 are variant alleles common to Asian ethnicities. The CYP2A6*7 and CYP2A6*8 alleles each contain a non-synonymous single nucleotide polymorphism (SNP) 6558T > C and 6600G > T, respectively, whereas the CYP2A6*10 haplotype allele contains both. We have developed the first haplo-typing assay; it can unambiguously distinguish the CYP2A6*7 CYP2A6*8 and CYP2A6*10 alleles. The allele frequencies of these three variants were assessed using the novel haplotyping assay in Chinese-Canadian (n = 112), Chinese-American (n = 221), Taiwanese (n = 319), Korean-American (n = 207) and Japanese-Canadian (n = 64) populations, as well as in Caucasian (n = 110) and African-Canadian (n = 113) populations. Our new method demonstrated higher frequencies of CYP2A6*7 and CYP2A6* 10, and a lower frequency of CYP2A6*8 in Asian populations, but no significant change of allele frequencies in Caucasian or African-Canadian populations. Pharmacogenetics and Genomics 15:189-192 (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:189 / 192
页数:4
相关论文
共 15 条
[1]   A novel single nucleotide polymorphism altering stability and activity of CYP2A6 [J].
Ariyoshi, N ;
Sawamura, Y ;
Kamataki, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (03) :810-814
[2]   METABOLISM OF NICOTINE TO COTININE STUDIED BY A DUAL STABLE-ISOTOPE METHOD [J].
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (05) :483-493
[3]  
FERNANDEZSALGUERO P, 1995, AM J HUM GENET, V57, P651
[4]   CYP2E1*1D regulatory polymorphism:: association with alcohol and nicotine dependence [J].
Howard, LA ;
Ahluwalia, JS ;
Lin, SK ;
Sellers, EM ;
Tyndale, RF .
PHARMACOGENETICS, 2003, 13 (06) :321-328
[5]  
Ikeda K, 2000, CLIN CANCER RES, V6, P4409
[6]  
Kiyotani Kazuma, 2002, Drug Metab Pharmacokinet, V17, P482, DOI 10.2133/dmpk.17.482
[7]  
Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
[8]   IDENTIFICATION OF THE HUMAN LIVER CYTOCHROME-P-450 RESPONSIBLE FOR COUMARIN 7-HYDROXYLASE ACTIVITY [J].
MILES, JS ;
MCLAREN, AW ;
FORRESTER, LM ;
GLANCEY, MJ ;
LANG, MA ;
WOLF, CR .
BIOCHEMICAL JOURNAL, 1990, 267 (02) :365-371
[9]  
Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212
[10]  
Nunoya KI, 1996, J PHARMACOL EXP THER, V277, P768